Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy.
Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy.
复制标题
DOI：
10.4137/cmo.s23252
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Nasu Y
中科院分区：
文献类型：
--
作者：
Kumon H;Sasaki K;Ariyoshi Y;Sadahira T;Ebara S;Hiraki T;Kanazawa S;Yanai H;Watanabe M;Nasu Y
一名患有转移性去势抵抗性前列腺癌（CRPC）的63岁男性在化疗后使用携带人REIC/Dkk-3基因的腺病毒载体（Ad-REIC）进行原位基因治疗成功治疗两年。Ad-REIC介导同时诱导癌症选择性细胞凋亡和增强抗肿瘤免疫，并且自2011年1月起在冈山大学医院进行了Ad-REIC的I/IIa期临床研究。2012年12月入组时，患者出现淋巴结（LN）转移快速进展。在CT引导下向转移性盆腔和主动脉旁淋巴结中进行两次预定的Ad-REIC注射和10次额外的Ad-REIC注射，平均间隔四周，显示出Ad-REIC作为治疗性癌症疫苗的有效直接和间接作用。在接下来的12个月内，对显示再生长的主动脉旁淋巴结进行三次额外注射，充分控制了所有前列腺特异性抗原（PSA）下降的转移性淋巴结，没有任何特定的不良事件。
A 63-year-old man with metastatic castration-resistant prostate cancer (CRPC) was successfully treated for two years with in situ gene therapy using an adenovirus vector carrying the human REIC/Dkk-3 gene (Ad-REIC), following chemotherapy. Ad-REIC mediates simultaneous induction of cancer-selective apoptosis and augmentation of antitumor immunity, and a Phase I/IIa clinical study on Ad-REIC has been conducted at Okayama University Hospital since January 2011. At the time of enrollment in December 2012, the patient presented with rapid progression of lymph node (LN) metastases. Two scheduled Ad-REIC injections and 10 additional Ad-REIC injections into metastatic pelvic and para-aortic LNs under CT guidance, with an average four weeks’ interval, exhibited the potent direct and indirect effects of Ad-REIC as a therapeutic cancer vaccine. During the next 12 months, three additional injections into para-aortic LNs showing regrowth achieved adequate control of all metastatic LNs with prostate-specific antigen (PSA) decline, without any particular adverse events.